Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment (BRISK PS)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Bristol-Myers Squibb. Recruitment status was Active, not recruiting
Study NCT00825955
Information provided by Bristol-Myers Squibb
First Received on January 20, 2009.
Last Updated on April 30, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
